Drug Trial Radar · NCT03996447
Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Last checked: Nov 20, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
260
Actual
Start
Jun 3, 2019
Primary completion
Sep 11, 2020
Study completion Sep 11, 2020
Sponsor
- Lead sponsor
- GuerbetIndustry
- Sponsor type
- Industry
- First posted
- Jun 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial aimed to evaluate the Efficacy and Safety of gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Conditions
- CNS Lesion
- Blood Brain Barrier Defect
Interventions
gadopiclenolDrug
single intravenous (IV) bolus injection at a rate of 2ml/second
Gadobutrol 1Mmol/mL Solution for Injection VialDrug
single intravenous (IV) bolus injection at a rate of 2ml/second
Primary outcomes
What the sponsor says the trial is designed to measure.
- Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRITime frame: At first MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 1. At second MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 2, performed 2-14 days after gadobutrol-enhanced MRI.
Locations
33 sites in 11 countries. Site status is shown where the registry gives one.
ASCLEPES Research Centers
Panorama City, California
University of Connecticut Health Center
Farmington, Connecticut
Northwestern Memorial Hospital
Chicago, Illinois
Northwest Neurology, Ltd.
Rolling Meadows, Illinois
University of Missouri Hospital and Clinic
Columbia, Missouri
University Of Pennsylvania
Philadelphia, Pennsylvania
South Carolina Clinical & Translational Research (SCTR) Institute
Charleston, South Carolina
University Of Washington - Medical Center
Seattle, Washington
ZNA Middelheim
Antwerp, Belgium
UZ Brussel - Campus Jette
Brussels, Belgium
CHRU - Hôpital Roger Salengro - Neurologie
Lille, France
Centre Hospitalier Sainte-Anne
Paris, France
CHU La Miletrie
Poitiers, France
CHRU Strasbourg Hôpital de Hautepierre
Strasbourg, France
Uniklinik Mannheim
Mannheim, Germany
Semmelweis Egyetem - Neurology
Budapest, Hungary
Orszagos Klinikai Idegtudomanyi Intezet
Budapest, Hungary
Debreceni Egyetem Klinikai Kozpont
Debrecen, Hungary
Pecsi Tudomanyegyetem Klinikai Kozpont - Idegsebeszeti Klinika
Pécs, Hungary
Szegedi Tudomanyegyetem AOK
Szeged, Hungary
ASL 1 Abruzzo Avezzano-Sulmona-L'Aquila, Ospedale Regionale San Salvatore
L’Aquila, Italy
Fondazione I.R.C.C.S. C.Mondino
Pavia, Italy
Istituto Neurologico Mediterraneo-Neuromed, I.R.C.C.S.
Pozzilli, Italy
Azienda Sanitaria Universitaria Integrata di Trieste-PO Cattinara
Trieste, Italy
Axis Heilsa S. de R.L. de C.V. (Althian)
Monterrey, Mexico
Clinical Research Institute S.C
Tlalnepantla, Mexico
Uniwersyteckie Centrum Kliniczne w Gdańsku, Zakład Radiologii
Gdansk, Poland
Konkuk University Medical Center
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Hospital del Mar
Barcelona, Spain
M.D. Anderson Cancer Center Madrid
Madrid, Spain
Hospital Clínico San Carlos
Madrid, Spain
Taipei Veterans General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.